RESUMO
OBJECTIVE: To evaluate the changes of plasma MMP-2, -9 levels in preeclampsia between antepartum and postpartum periods, and compare with normotensive pregnant. METHODS: Plasma MMP-2, -9 levels were determined with enzyme-linked immunoassay in pregnant women with preeclampsia (n=20) compared to control group (normotensive pregnant women) matched by maternal age, gestational age, and parity (n=20). RESULTS: Women with preeclampsia presented significantly higher plasma level of MMP-2 before delivery [516.33 +/- 98.75 vs 384.55 +/- 93.84 (ng/mL), p=0.002]. In postpartum 24 hours, women with preeclampsia exhibited higher plasma MMP-2 level compared control group [534.77 +/- 158.67 vs 336.04 +/- 139.11 (ng/mL), p=0.002]. But the plasma level of MMP-9 was significantly lower in preeclampsia group before delivery [26.26 +/- 7.49 vs 45.00 +/- 20.31 (ng/mL), p=0.001]. In postpartum 24 hours, women with preeclampsia also speculated lower plasma MMP-9 level compared control group, but no existence of significance. CONCLUSION: Plasma MMP-2 concentration is significantly increased in preeclampsia before delivey and postpartum 24 hours. Plasma MMP-9 concentration is significantly decreased in preeclampsia before delivery.
Assuntos
Feminino , Humanos , Idade Gestacional , Imunoensaio , Idade Materna , Metaloproteinase 2 da Matriz , Metaloproteinase 9 da Matriz , Paridade , Plasma , Período Pós-Parto , Pré-Eclâmpsia , GestantesRESUMO
OBJECTIVE: To evaluate the changes of plasma MMP-2, -9 levels in preeclampsia between antepartum and postpartum periods, and compare with normotensive pregnant. METHODS: Plasma MMP-2, -9 levels were determined with enzyme-linked immunoassay in pregnant women with preeclampsia (n=20) compared to control group (normotensive pregnant women) matched by maternal age, gestational age, and parity (n=20). RESULTS: Women with preeclampsia presented significantly higher plasma level of MMP-2 before delivery [516.33 +/- 98.75 vs 384.55 +/- 93.84 (ng/mL), p=0.002]. In postpartum 24 hours, women with preeclampsia exhibited higher plasma MMP-2 level compared control group [534.77 +/- 158.67 vs 336.04 +/- 139.11 (ng/mL), p=0.002]. But the plasma level of MMP-9 was significantly lower in preeclampsia group before delivery [26.26 +/- 7.49 vs 45.00 +/- 20.31 (ng/mL), p=0.001]. In postpartum 24 hours, women with preeclampsia also speculated lower plasma MMP-9 level compared control group, but no existence of significance. CONCLUSION: Plasma MMP-2 concentration is significantly increased in preeclampsia before delivey and postpartum 24 hours. Plasma MMP-9 concentration is significantly decreased in preeclampsia before delivery.
Assuntos
Feminino , Humanos , Idade Gestacional , Imunoensaio , Idade Materna , Metaloproteinase 2 da Matriz , Metaloproteinase 9 da Matriz , Paridade , Plasma , Período Pós-Parto , Pré-Eclâmpsia , GestantesRESUMO
The breast cancer is the second most common malignancy in pregnancy after cervical cancer. Pregnancy- associated breast caner tends to show unfavorable prognosis, because it is diagnosed at more advanced stage due to delay of diagnosis and treatment. For appropriate management, collaboration with physicians and obstetricians should make precise decisions considering gestational weeks and cancer stage at the time of diagnosis in a point of view from mother and fetus. A case of successful gestation and delivery after chemotherapy in a woman with inflammatory breast cancer diagnosed in the second trimester is presented with review of literature.
Assuntos
Feminino , Humanos , Gravidez , Neoplasias da Mama , Mama , Comportamento Cooperativo , Diagnóstico , Tratamento Farmacológico , Feto , Neoplasias Inflamatórias Mamárias , Mães , Segundo Trimestre da Gravidez , Prognóstico , Neoplasias do Colo do ÚteroRESUMO
Osteogenesis imperfecta (OI) is an inherited disease of connective tissue disorder which represents a phenotypically heterogeneous group of conditions that results from a number of genetic defects in the synthesis of type I collagen. A pregnancy associated with osteogenesis imperfecta is considered a high risk pregnancy because the disease is associated with various metabolic and hematologic disorders, as well as well-recongnized skeletal abnormalities. In addition to the mother with OI, the offspring has about a 25% to 50% chance of being affected, therefore genetic counseling before conception and prenatal diagnosis should be offered to all affected mothers. Patients with OI present a series of problems and require a multidisciplinary approach in their management. We present a case of parturient with osteogenesis imperfecta with brief review of literature.
Assuntos
Humanos , Gravidez , Colágeno Tipo I , Tecido Conjuntivo , Fertilização , Aconselhamento Genético , Hereditariedade , Mães , Osteogênese Imperfeita , Osteogênese , Gravidez de Alto Risco , Diagnóstico Pré-NatalRESUMO
During the past few years much effort has been put into simplifying the clinical man-agement of in-vitro fertilization/embryo transfer cycles. One important step was the intro-duction of transvaginal ultrasound-guided oocyte collection, as previously described. This study describes further simplifications in the clinical management of ovarian stimulation and luteal support, and in-vitro fertilization procedure. During the period from October 1994 to September 1995, two major simplification steps were introduced. All cycles were administe-red with a gonadotrophin-releasing hormone agonist according to a long or short protocol preventing premature LH surge. During period I (Group I, n=62 cycles), closer monitoring by several pelvic ultrasound scans and serum oestradiol was used for monitoring the ovarian stimulation ; HTF media with fetal cord serum was used for insemination, growth and tran-sfer media in IVF-ET procedure ; progesterine in oil was daily used by intramuscular injec-tion for luteal support. During period II(Group II-I, n=71 cycles), only several ultrasound scans were used for monitoring the ovarian cycle ; Medi-cult IVF media containing synthetic serum replacement was used for insemination, growth and transfer media; Progesterine in oil was used daily by intramuscular injection for luteal support. During period III(Group II-II, n=16 cycles), further simplification of the clinical management was introduced by using a intravaginal micronized progesterone(Utrogestan) for luteal support. Retrospective analysis between Group I and Group II showed no differences in the number of oocyte(13.2+/-0.8/14.6+/-1.0), fertilization rate(71.5 %/60.7 %), cleavage rate(63.6 %/57.9 %), number of embryos transfered(5.0+/-0.5/4.5+/-0.5). Ongoing pregnancy rates obta ined from the three groups(Group I, Group II-1, Group II-II) were 25.8 %, 25 % and 40 %, respectively(p=ns). But introduction of minimal monitoring gave a significant reduction in the average number of US measurements in the simplified groups(Group II) compared with the group using the conventional monitoring protocol(Group I)(3.8+/-1.0/8.7+/-2.8, p<0.05). In the above groups, five patients developed severe OHSS but there was no differenc e in the distribution. Conclusively, simplified protocols including minimal follicle monitoring only by US, IVF-ET with Medi-cult IVF media containing synthetic serum replacement and the luteal support with intravaginal micronized progesterone gave a increased efficacy of the clinical phase of IVF treatment without a reduction in the success rate.
Assuntos
Feminino , Humanos , Meios de Cultura Livres de Soro , Transferência Embrionária , Estruturas Embrionárias , Estradiol , Fertilização , Injeções Intramusculares , Inseminação , Ciclo Menstrual , Recuperação de Oócitos , Indução da Ovulação , Taxa de Gravidez , Progesterona , Estudos Retrospectivos , UltrassonografiaRESUMO
No abstract available.
Assuntos
Humanos , Sítios de Ligação , Gonadotropinas , Neoplasias OvarianasRESUMO
No abstract available.